205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.84%
Revenue growth above 1.5x MRVL's 6.87%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
16.44%
Gross profit growth above 1.5x MRVL's 7.09%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
26.41%
EBIT growth 50-75% of MRVL's 46.35%. Martin Whitman would suspect suboptimal resource allocation.
13.75%
Operating income growth under 50% of MRVL's 46.35%. Michael Burry would be concerned about deeper cost or sales issues.
0.48%
Net income growth under 50% of MRVL's 52.30%. Michael Burry would suspect the firm is falling well behind a key competitor.
2.63%
EPS growth under 50% of MRVL's 45.45%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
No Data
No Data available this quarter, please select a different quarter.
-0.55%
Share reduction while MRVL is at 1.28%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.36%
Reduced diluted shares while MRVL is at 1.56%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-99.94%
Dividend reduction while MRVL stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
83.07%
OCF growth above 1.5x MRVL's 36.49%. David Dodd would confirm a clear edge in underlying cash generation.
86.67%
FCF growth above 1.5x MRVL's 34.40%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-2.77%
Negative 10Y revenue/share CAGR while MRVL stands at 415.23%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
20.39%
5Y revenue/share CAGR under 50% of MRVL's 415.23%. Michael Burry would suspect a significant competitive gap or product weakness.
68.07%
3Y revenue/share CAGR under 50% of MRVL's 267.94%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
175.37%
10Y OCF/share CAGR under 50% of MRVL's 1007.00%. Michael Burry would worry about a persistent underperformance in cash creation.
228.76%
Below 50% of MRVL's 1007.00%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
182.00%
3Y OCF/share CAGR under 50% of MRVL's 11152.72%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
102.53%
Below 50% of MRVL's 1324.45%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-1.52%
Negative 5Y net income/share CAGR while MRVL is 1324.45%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
253.22%
3Y net income/share CAGR above 1.5x MRVL's 135.12%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
186.13%
Below 50% of MRVL's 912.84%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
1.13%
Below 50% of MRVL's 912.84%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
12.65%
Positive short-term equity growth while MRVL is negative. John Neff sees a strong advantage in near-term net worth buildup.
-99.93%
Cut dividends over 10 years while MRVL stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-99.92%
Negative 5Y dividend/share CAGR while MRVL stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-99.93%
Negative near-term dividend growth while MRVL invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
0.68%
AR growth is negative/stable vs. MRVL's 18.49%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
-3.66%
Inventory is declining while MRVL stands at 11.19%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.44%
Asset growth at 50-75% of MRVL's 5.03%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
4.15%
BV/share growth above 1.5x MRVL's 2.69%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-0.83%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
6.90%
R&D growth drastically higher vs. MRVL's 3.66%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
20.35%
SG&A growth well above MRVL's 4.23%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.